|
|
|
UK/global turnover: |
£70m/£658.4m |
UK/global PEP: |
£765,000/£765,000 |
UK/global revenue per lawyer: |
£824,000/£414,000 |
UK revenue per partner/equity partner: |
£2.92m/£2.9m |
Global revenue per equity partner: |
£1.3m |
UK/global number of partners: |
24/495 |
| UK/global number of lawyers: |
85/1,592 |
| UK number of staff: |
172 |
| UK/global leverage ratio: |
2.5/2.2 |
| UK equity partner to staff ratio: |
7.2 |
LATHAM & WATKINS had a very good 2004-
05. London's gross revenues leapt 40 per cent
to £70m, up from £50m in 2002-03, shooting
Latham into the top three in the international
rankings. The growth was largely attributed to
the capital markets push, principally for highyield.
This was driven off the back of the firm's
expertise in the US; however, it also snared
highly rated capital markets specialist Ian Clark
from White & Case in May 2004.
The firm's policy of allowing clients to
choose their billing currency also assisted to
increase the percentage completed in sterling
and had the follow-on effect of hedging the
firm against the poor performance of the US
dollar.
Highlights included advising Deutsche
Bank, one of the largest distressed debt
creditors of British Energy, on its distressed
debt acquisition strategy. London also advised
Autostrade in its €10bn (£6.78bn) global
medium-term note programme and the €6.5bn (£4.41bn) issuance of notes. The firm
advised Epigenomics on its IPO of 4,621,849
new shares on the Frankfurt Stock Exchange,
the first biotech IPO in Germany since 2001.
|
| |
|
|
|
